EUVIMEDEUVIMED entdecken
Crossref

Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets

Peng Zhang, Zhiyong Qi, Huajie Xu, Luning Zhou, Xin Zhao, Haoxuan Zhong, Wenxuan Zhou, Bing Fan, Hongyi Wu, Junbo Ge iD

Cardiovascular Research · 2025

DOI: 10.1093/cvr/cvaf096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2025. Verfasst von Peng Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai 200032, Chi…. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Non-alcoholic Fatty Liver Disease, Blood Platelets, alpha-2-HS-Glycoprotein. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 75 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Clinical Research Special Fund of Zhongshan Hospital Fudan University, Shanghai Medical College of Fudan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Fetuin-A, a liver-derived heterodimeric plasma glycoprotein, exhibits abnormal elevation in non-alcoholic fatty liver disease (NAFLD). Plasma fetuin-A levels correlate closely with both morbidity and mortality associated with cardiovascular diseases. However, the precise influence of fetuin-A on NAFLD-related platelet activation and thrombosis remains to be elucidated. Methods and results Fetuin-A directly amplified agonist-induced platelet aggregation, dense granule adenosine triphosphate release, P-selectin exposure, integrin αIIbβ3 activation, spreading, and clot retraction. Mechanistically, fetuin-A bound to platelet Toll-like receptor-4 (TLR-4), activating TLR-4/MyD88, SFK/PI3 K/AKT, cGMP/PKG, and mitogen-activated protein kinase signalling pathways to enhance platelet activation. TLR-4 specific antagonist TAK-242 and TLR-4-deficient mice confirmed the TLR-4 dependence of these effects. Oral administration of firsocostat, rosuvastatin, or pioglitazone demonstrated efficacy in alleviating thrombosis formation in NAFLD mice by reducing fetuin-A levels and attenuating platelet hyperreactivity. Notably, the fetuin-A-inhibiting antibody potently suppressed platelet activation and inhibited thrombosis formation in NAFLD mice. Administration of this antibody attenuated thromboembolism and microvascular thrombosis in NAFLD mice, thereby safeguarding the lung, heart, and brain from exacerbated tissue infarcts. Finally, a positive correlation between plasma fetuin-A concentration and platelet aggregation was observed in NAFLD patients.

Conclusion

Fetuin-A emerges as a positive regulator of platelet hyperreactivity in NAFLD. Acting via TLR-4-dependent signalling pathways, plasma fetuin-A directly amplifies platelet activation and promotes in vivo thrombosis. Firsocostat, rosuvastatin, and pioglitazone abrogate these enhancing effects by reducing fetuin-A levels. The fetuin-A-inhibiting antibody presents potential therapeutic advantages to prevent thrombotic complications in NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 4Non-alcoholic Fatty Liver DiseaseBlood Plateletsalpha-2-HS-GlycoproteinThrombosisAnimalsHumansSignal TransductionDisease Models, AnimalMaleMice, KnockoutMice, Inbred C57BLPlatelet AggregationProtein BindingPlatelet ActivationFemaleMiddle AgedCase-Control Studies

Stichwörter der Autor:innen

Cardiovascular diseasesFetuin-ANon-alcoholic fatty liver diseasePlatelet hyperreactivityThrombosis

Substanzen

Toll-Like Receptor 4alpha-2-HS-GlycoproteinTlr4 protein, mouseTLR4 protein, humanAHSG protein, human

Autor:innen und Institutionen

  • Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases, 180 Fenglin Road, Shanghai 200032, China.
  • Department of Infectious Disease, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
  • State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
  • NHC Key Laboratory of Ischaemic Heart Diseases, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
  • Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.
  • National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai 200032, China.

ORCID-Profile: Junbo Ge

Förderung

  • National Natural Science Foundation of China
  • Clinical Research Special Fund of Zhongshan Hospital Fudan University
  • Shanghai Medical College of Fudan University
  • Shanghai sailing program
  • Shanghai Municipal Key Clinicial Specialty
  • 2021 clinical research navigation project of Shanghai Medical College of Fudan University

Zitieren

APA

Zhang, P., Qi, Z., Xu, H., Zhou, L., Zhao, X., Zhong, H., Zhou, W., Fan, B., Wu, H., & Ge, J. (2025). Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets. Cardiovascular Research. https://doi.org/10.1093/cvr/cvaf096

Vancouver

Zhang P, Qi Z, Xu H, Zhou L, Zhao X, Zhong H, et al. Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets. Cardiovascular Research. 2025. doi:10.1093/cvr/cvaf096

BibTeX
@article{Zhang2025,
  author = {Zhang, Peng and Qi, Zhiyong and Xu, Huajie and Zhou, Luning and Zhao, Xin and Zhong, Haoxuan and Zhou, Wenxuan and Fan, Bing and Wu, Hongyi and Ge, Junbo},
  title = {Fetuin-A increases thrombosis risk in non-alcoholic fatty liver disease by binding to TLR-4 on platelets},
  journal = {Cardiovascular Research},
  year = {2025},
  doi = {10.1093/cvr/cvaf096}
}
Kostenlos starten →